TCIM
LGND icon

TIAA CREF Investment Management’s Ligand Pharmaceuticals LGND Stock Holding History

TIAA CREF Investment Management’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$9.37M Sell
119,464
-732
-0.6% -$55.5K 0.01% 1071
2018
Q4 		$10.2M Sell
120,196
-1,959
-2% -$209K 0.01% 948
2018
Q3 		$20.9M Sell
122,155
-6,168
-5% -$930K 0.01% 719
2018
Q2 		$16.6M Buy
128,323
+10,318
+9% +$1.15M 0.01% 847
2018
Q1 		$12.2M Buy
118,005
+27,940
+31% +$2.76M 0.01% 1007
2017
Q4 		$7.69M Sell
90,065
-5,889
-6% -$510K 0.01% 1313
2017
Q3 		$8.15M Sell
95,954
-1,659
-2% -$131K 0.01% 1283
2017
Q2 		$7.39M Buy
97,613
+6,902
+8% +$483K 0.01% 1323
2017
Q1 		$5.99M Sell
90,711
-5,809
-6% -$382K ﹤0.01% 1477
2016
Q4 		$6.12M Sell
96,520
-125,290
-56% -$7.91M ﹤0.01% 1471
2016
Q3 		$14.1K Buy
221,810
+44,228
+25% +$3.25M 0.01% 930
2016
Q2 		$13.2M Buy
177,582
+3,063
+2% +$227K 0.01% 911
2016
Q1 		$11.7M Buy
174,519
+73,070
+72% +$4.44M 0.01% 973
2015
Q4 		$6.86M Sell
101,449
-2,817
-3% -$174K 0.01% 1318
2015
Q3 		$5.57M Sell
104,266
-12,261
-11% -$744K ﹤0.01% 1465
2015
Q2 		$7.33M Sell
116,527
-8,239
-7% -$450K 0.01% 1380
2015
Q1 		$6M Sell
124,766
-3,322
-3% -$127K ﹤0.01% 1498
2014
Q4 		$4.25M Sell
128,088
-9,028
-7% -$294K ﹤0.01% 1738
2014
Q3 		$4.02M Sell
137,116
-208,938
-60% -$6.94M ﹤0.01% 1769
2014
Q2 		$13.4M Buy
346,054
+56,937
+20% +$2.31M 0.01% 974
2014
Q1 		$12.1M Buy
289,117
+54,673
+23% +$2.28M 0.01% 1017
2013
Q4 		$7.69M Buy
234,444
+118,491
+102% +$3.86M 0.01% 1328
2013
Q3 		$3.13M Sell
115,953
-4,549
-4% -$128K ﹤0.01% 1922
2013
Q2 		$2.81M Buy
+120,502
New +$2.17M ﹤0.01% 1944

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
CCMLC
Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
CCA
Conestoga Capital Advisors Wayne, Pennsylvania $5.01B AUM 6.26% 1-Year Est. Return
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return

TIAA CREF Investment Management's LGND Position: Q1 2019 in Review

TIAA CREF Investment Management reduced its Ligand Pharmaceuticals (LGND) stake by 0.61% in Q1 2019, selling an estimated $55.5K and leaving 119,464 shares worth $9.37M. The position accounts for 0.01% of the portfolio, ranked #1071.

TIAA CREF Investment Management first reported a position in LGND in Q2 2013 and has held it in 24 quarters since. The position peaked at $20.9M in Q3 2018. 330 funds tracked by Wall St. Rank hold LGND as of Q1 2019.

  • TIAA CREF Investment Management held 119,464 shares of Ligand Pharmaceuticals worth $9.37M as of Q1 2019.
  • TIAA CREF Investment Management sold 732 Ligand Pharmaceuticals shares in Q1 2019, an estimated $55.5K.
  • Ligand Pharmaceuticals made up 0.01% of TIAA CREF Investment Management's portfolio in Q1 2019, its #1071 holding.
  • TIAA CREF Investment Management first reported a position in Ligand Pharmaceuticals in Q2 2013 and has held it in 24 quarters since.
  • TIAA CREF Investment Management's Ligand Pharmaceuticals position peaked at $20.9M in Q3 2018.
  • 330 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2019.

Based on TIAA CREF Investment Management's 13F filing for Q1 2019, filed 14 May 2019.